XVIVO (Xvivo Perfusion AB) vs OMX Stockholm 30 Comparison

XVIVO

OMX Stockholm 30

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

XVIVO

OMX Stockholm 30

Difference

1Y 3Y 5Y 10Y 15Y 20Y

XVIVO

OMX Stockholm 30

Add Stock

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

OMX Stockholm 30

XVIVO

7741

ALC

COLO B

ALGN

Add Stock

1Y 3Y 5Y 10Y 15Y 20Y

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Xvivo Perfusion AB
Glance View

Market Cap

15.8B SEK

Industry

Health Care

Nestled within the innovative landscape of Gothenburg, Sweden, Xvivo Perfusion AB stands at the forefront of transforming organ transplantation. Founded with the mission to tackle the chronic shortage of viable organs for transplant, Xvivo focuses primarily on improving the quality and availability of donor organs. At the heart of their operations is the development of advanced perfusion systems and solutions that enhance the viability of organs during transport and storage. By extending the window within which organs can remain functional outside the body, Xvivo's technology dramatically improves the chances of successful transplantation, while simultaneously expanding the pool of usable organs. Their product portfolio includes systems such as the XPS (Xvivo Perfusion System) and STEEN Solution™, specifically designed for lung and other visceral transplants to keep organs in optimal condition until the moment they are surgically implanted. Xvivo Perfusion monetizes its innovations through the sale of its proprietary equipment, perfusion liquids, and accompanying services to hospitals and transplant centers worldwide. The company strategically leverages its expertise in perfusion technology to not only enhance procedures but also cater to niche markets like ex vivo lung perfusion (EVLP), which provides additional preparation and evaluation of the organs before transplantation. Contracts, collaborative partnerships with research institutions, and long-term relationships nurtured within the medical community fuel Xvivo's growth trajectory. Additionally, their business model includes potential expansions into other areas of organ care and preservation, promising a future where transplant medicine continues to evolve, setting new standards and saving more lives. With sustained investments in research and a proactive approach to regulatory needs, Xvivo maintains its position as a crucial player within this life-saving industry, combining advanced science with compassionate healthcare solutions.

View XVIVO Analysis

XVIVO Intrinsic Value

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

JP		Hoya Corp TSE:7741	Add
CH		Alcon AG SIX:ALC	Add
DK		Coloplast A/S CSE:COLO B	Add
US		Align Technology Inc NASDAQ:ALGN	Add
KR	H	HLB Inc KOSDAQ:028300	Add
CN		Shenzhen New Industries Biomedical Engineering Co Ltd SZSE:300832	Add
US		Lantheus Holdings Inc NASDAQ:LNTH	Add
CA		Bausch + Lomb Corp NYSE:BLCO	Add
UK		ConvaTec Group PLC LSE:CTEC	Add
US		Merit Medical Systems Inc NASDAQ:MMSI	Add

JP		Hoya Corp TSE:7741	Select
CH		Alcon AG SIX:ALC	Select
DK		Coloplast A/S CSE:COLO B	Select
US		Align Technology Inc NASDAQ:ALGN	Select
KR	H	HLB Inc KOSDAQ:028300	Select
CN		Shenzhen New Industries Biomedical Engineering Co Ltd SZSE:300832	Select
US		Lantheus Holdings Inc NASDAQ:LNTH	Select
CA		Bausch + Lomb Corp NYSE:BLCO	Select
UK		ConvaTec Group PLC LSE:CTEC	Select
US		Merit Medical Systems Inc NASDAQ:MMSI	Select

JP		Hoya Corp TSE:7741	Add
CH		Alcon AG SIX:ALC	Add
DK		Coloplast A/S CSE:COLO B	Add
US		Align Technology Inc NASDAQ:ALGN	Add
KR	H	HLB Inc KOSDAQ:028300	Add
CN		Shenzhen New Industries Biomedical Engineering Co Ltd SZSE:300832	Add
US		Lantheus Holdings Inc NASDAQ:LNTH	Add
CA		Bausch + Lomb Corp NYSE:BLCO	Add
UK		ConvaTec Group PLC LSE:CTEC	Add
US		Merit Medical Systems Inc NASDAQ:MMSI	Add

HR	C	CROBEX INDX:CRBEX	Add
SA	T	Tadawul All Share INDX:TASI	Add
TH	S	SET Index INDX:SET	Add
ID	J	Jakarta Composite Index INDX:JKSE	Add
GR	A	Athens General Composite INDX:ATG	Add
BR	B	BOVESPA INDX:BVSP	Add
AR	S	S&P Merval INDX:MERV	Add
MX	M	Mexico S&P/BMV IPC INDX:MXX	Add
CZ	P	PX Prague Stock Index INDX:PX	Add
RU	M	MOEX Russia INDX:IMOEX	Add

	Franklin Covey Co NYSE:FC	35.3 USD 0.17%
	Mohawk Industries Inc NYSE:MHK	118.28 USD 0.84%
	Ardmore Shipping Corp NYSE:ASC	12.56 USD -1.64%
	ASGN Inc NYSE:ASGN	86.92 USD 0.67%
	Skyworks Solutions Inc NASDAQ:SWKS	92.63 USD -0.03%
	Weatherford International PLC NASDAQ:WFRD	72.13 USD -3.57%

XVIVO

vs

OMX Stockholm 30

Stocks Performance
XVIVO vs OMX Stockholm 30

Performance Gap
XVIVO vs OMX Stockholm 30

Performance By Year
XVIVO vs OMX Stockholm 30

Competitors Performance
Xvivo Perfusion AB vs Peers

Xvivo Perfusion AB
Glance View

Company

Help

Tools

Stocks

	Johnson & Johnson NYSE:JNJ	142.27 USD -2.71%
	Bank of America Corp NYSE:BAC	46.21 USD 0.28%
	Mastercard Inc NYSE:MA	516.4 USD 0.98%
	Salesforce Inc NYSE:CRM	326.9 USD 0.61%
	Abbvie Inc NYSE:ABBV	178.5 USD -0.57%
	Home Depot Inc NYSE:HD	387.2 USD 0.77%

	Arista Networks Inc NYSE:ANET	115.51 USD 0.19%
	Visa Inc NYSE:V	312.6 USD 0.3%
	Texas Pacific Land Corp NYSE:TPL	1 275.94 USD 1.4%
	KLA Corp NASDAQ:KLAC	686.2 USD -0.45%
	Manhattan Associates Inc NASDAQ:MANH	272.49 USD 1.6%
	Pinduoduo Inc NASDAQ:PDD	100.32 USD -0.3%

	Salesforce Inc NYSE:CRM	326.9 USD 0.61%
	ServiceNow Inc NYSE:NOW	1 049.08 USD -0.48%
	EOG Resources Inc NYSE:EOG	128.46 USD 0.71%
	Copart Inc NASDAQ:CPRT	56.78 USD 0.96%
	Applied Materials Inc NASDAQ:AMAT	176.99 USD -0.47%
	Synopsys Inc NASDAQ:SNPS	502 USD 2.95%

	Johnson & Johnson NYSE:JNJ	142.27 USD -2.71%
	Berkshire Hathaway Inc NYSE:BRK.A	677 925 USD -0.09%
	Bank of America Corp NYSE:BAC	46.21 USD 0.28%
	Mastercard Inc NYSE:MA	516.4 USD 0.98%
	UnitedHealth Group Inc NYSE:UNH	524.52 USD 2%
	Exxon Mobil Corp NYSE:XOM	106.93 USD -1.67%

XVIVO vs OMX Stockholm 30

Stocks Performance XVIVO vs OMX Stockholm 30

Performance Gap XVIVO vs OMX Stockholm 30

Performance By Year XVIVO vs OMX Stockholm 30

Competitors Performance Xvivo Perfusion AB vs Peers

Xvivo Perfusion AB Glance View

Company

Help

Tools

Stocks

XVIVO

vs

OMX Stockholm 30

Stocks Performance
XVIVO vs OMX Stockholm 30

Performance Gap
XVIVO vs OMX Stockholm 30

Performance By Year
XVIVO vs OMX Stockholm 30

Competitors Performance
Xvivo Perfusion AB vs Peers

Xvivo Perfusion AB
Glance View